NATIONAL BANK OF CANADA /FI/ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.

Quarter-by-quarter ownership
NATIONAL BANK OF CANADA /FI/ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$2,864
+67.3%
1550.0%0.00%
Q2 2023$1,712
+34.3%
155
+63.2%
0.00%
Q1 2023$1,275
+8.3%
950.0%0.00%
Q4 2022$1,177
+17.7%
95
+72.7%
0.00%
Q3 2022$1,0000.0%550.0%0.00%
Q2 2022$1,0000.0%550.0%0.00%
Q1 2022$1,0000.0%550.0%0.00%
Q4 2021$1,000550.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders